Psoriatic Arthritis Market Research
What is Psoriatic Arthritis (PsA)?
Psoriatic arthritis (PsA) is a chronic autoimmune condition that affects the joints and skin. Psoriatic arthritis typically develops in patients who have already been diagnosed with psoriasis (PsO), though it is possible for patients to develop psoriatic arthritis before psoriasis symptoms appear. According to the National Psoriasis Foundation, psoriatic arthritis affects about 30% of people with psoriasis. The most common symptoms of psoriatic arthritis are tendon pain and swelling, swelling of appendages (fingers and toes), changes to nails, and effects to the eyes including eye pain, redness, and inflammation. Psoriatic arthritis can range in severity, though left untreated, it may damage joints. There is no cure for psoriatic arthritis, but there are many advanced treatments currently on the market to help manage the condition. These include: Otezla (apremilast), Cimzia (certolizumab), Cosentyx (secukinumab), Enbrel (etanercept), Humira (adalimumab), Amjevita (adalimumab), Taltz (ixekizumab), Simponi (golimumab), Tremfya (guselkumab), Skyrizi (risankizumab), Xeljanz (tofacitinib), Rinvoq (upadacitinib), Remicade (infliximab), Avsola (infliximab), Inflectra (infliximab), Renflexis (infliximab), Unbranded Infliximab, Stelara (ustekinumab), and Orencia (abatacept).
Spherix Global Insights – Rheumatology – Psoriatic Arthritis
Spherix Global Insights’ rheumatology therapeutic team is a leading provider of independent syndicated psoriatic arthritis market research, insights, business intelligence & advisory services.
On an annual basis, Spherix’s rheumatology team publishes six (6) studies in psoriatic arthritis including:
• Realtime Dynamix™: Psoriatic Arthritis (US)
• Realtime Dynamix™: Psoriatic Arthritis (EU5)
• Launch Dynamix™: Rinvoq (AbbVie) in Psoriatic Arthritis (US)
• Launch Dynamix™: Skyrizi (AbbVie) in Psoriatic Arthritis (US)
• Launch Dynamix™: Bimzelx (UCB) in Psoriatic Arthritis (US)*
• Patient Chart Dynamix™: Biologic/Small Molecule Switching in Psoriatic Arthritis (US)
*Pending approvals and launch
Spherix’s RealTime Dynamix™ service includes quarterly or semiannual reports, respectively in the US and EU, providing an unbiased view of the competitive landscape within the psoriatic arthritis market.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports covering promotional activity, barriers to uptake, and patient types being identified for the launch brand.
Spherix’s Patient Chart Dynamix™ service includes patient level data detailing clinical and non-clinical patient demographics, along with rationale for treatment choices. It reveals real patient management patterns through rigorous analysis of large-scale patient chart audits.
Follow Spherix Rheumatology on Social Media
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: